Berenberg Gives Inchcape PLC (LON:INCH) GBX 825.00 Target; National Planning Upped Intercept Pharmaceuticals In (ICPT) Stake By $632,490

Berenberg was cut to Hold and currently has GBX 825.00 target price on Inchcape PLC (LON:INCH)‘s stock. This was shared with investors and clients in analysts report on Tuesday, 16 January.

National Planning Corp increased Intercept Pharmaceuticals In (ICPT) stake by 20.89% reported in 2017Q3 SEC filing. National Planning Corp acquired 10,905 shares as Intercept Pharmaceuticals In (ICPT)’s stock declined 12.60%. The National Planning Corp holds 63,100 shares with $3.66 million value, up from 52,195 last quarter. Intercept Pharmaceuticals In now has $1.38B valuation. The stock increased 1.18% or $0.64 during the last trading session, reaching $54.95. About 516,710 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 14.52% since January 16, 2017 and is downtrending. It has underperformed by 31.22% the S&P500.

Among 11 analysts covering Inchcape PLC (LON:INCH), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Inchcape PLC has GBX 1050 highest and GBX 680 lowest target. GBX 864.36’s average target is 13.21% above currents GBX 763.5 stock price. Inchcape PLC had 121 analyst reports since July 24, 2015 according to SRatingsIntel. Numis Securities maintained the shares of INCH in report on Tuesday, September 15 with “Hold” rating. As per Friday, May 27, the company rating was maintained by Deutsche Bank. The rating was maintained by Deutsche Bank with “Hold” on Friday, March 4. JP Morgan maintained Inchcape plc (LON:INCH) on Thursday, March 2 with “Overweight” rating. HSBC maintained it with “Buy” rating and GBX 1030 target in Wednesday, May 17 report. The rating was maintained by Deutsche Bank with “Hold” on Tuesday, October 20. Deutsche Bank upgraded Inchcape plc (LON:INCH) rating on Monday, July 4. Deutsche Bank has “Buy” rating and GBX 835 target. The company was maintained on Friday, March 3 by Berenberg. The rating was maintained by HSBC with “Buy” on Friday, May 26. HSBC maintained the shares of INCH in report on Monday, March 7 with “Buy” rating.

The stock decreased 1.80% or GBX 14 during the last trading session, reaching GBX 763.5. About 252,990 shares traded. Inchcape plc (LON:INCH) has 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Inchcape plc operates as an automotive distributor and retailer in the premium and luxury automotive sectors. The company has market cap of 3.16 billion GBP. The firm sells and retails new and used cars of various brands. It has a 15.97 P/E ratio. It also provides after sales servicing and parts; and vehicle finance and insurance services and products.

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 2 Sell and 9 Hold. Therefore 52% are positive. Intercept Pharmaceuticals has $423 highest and $50.0 lowest target. $164.94’s average target is 200.16% above currents $54.95 stock price. Intercept Pharmaceuticals had 65 analyst reports since August 10, 2015 according to SRatingsIntel. Goldman Sachs initiated Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Wednesday, March 30. Goldman Sachs has “Neutral” rating and $114 target. The rating was initiated by Morgan Stanley with “Underweight” on Thursday, August 13. As per Tuesday, September 12, the company rating was maintained by Cowen & Co. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Outperform” rating given on Friday, December 30 by Wedbush. The stock has “Buy” rating by Wedbush on Friday, September 15. The rating was maintained by JMP Securities on Tuesday, May 31 with “Market Outperform”. The firm has “Neutral” rating by Citigroup given on Friday, September 22. Wells Fargo upgraded the shares of ICPT in report on Tuesday, April 5 to “Outperform” rating. The rating was maintained by Oppenheimer with “Buy” on Monday, July 31. The firm earned “Outperform” rating on Thursday, April 7 by BMO Capital Markets.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: